Free Trial

ResMed (RMD) Stock Forecast & Price Target

ResMed logo
$272.90 +0.30 (+0.11%)
As of 03:03 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

ResMed - Analysts' Recommendations and Stock Price Forecast (2025)

Consensus Rating

Sell
1
Hold
3
Buy
13

Based on 17 Wall Street analysts who have issued ratings for ResMed in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 17 analysts, 1 has given a sell rating, 3 have given a hold rating, 11 have given a buy rating, and 2 have given a strong buy rating for RMD.

Consensus Price Target

$278.36
2.00% Upside
According to the 17 analysts' twelve-month price targets for ResMed, the average price target is $278.36. The highest price target for RMD is $325.00, while the lowest price target for RMD is $180.00. The average price target represents a forecasted upside of 2.00% from the current price of $272.90.
MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
Get the Latest News and Ratings for RMD and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for ResMed and its competitors.

Sign Up
By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

RMD Analyst Ratings Over Time

TypeCurrent Forecast
9/17/24 to 9/17/25
1 Month Ago
8/18/24 to 8/18/25
3 Months Ago
6/19/24 to 6/19/25
1 Year Ago
9/18/23 to 9/17/24
Strong Buy
2 Strong Buy rating(s)
2 Strong Buy rating(s)
1 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
11 Buy rating(s)
10 Buy rating(s)
8 Buy rating(s)
5 Buy rating(s)
Hold
3 Hold rating(s)
3 Hold rating(s)
5 Hold rating(s)
6 Hold rating(s)
Sell
1 Sell rating(s)
1 Sell rating(s)
1 Sell rating(s)
0 Sell rating(s)
Consensus Price Target$278.36$274.83$259.33$204.70
Forecasted Upside2.00% Upside-3.96% Downside3.37% Upside-18.41% Downside
Consensus RatingModerate BuyModerate BuyModerate BuyHold

RMD Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

RMD Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

ResMed Stock vs. The Competition

TypeResMedMedical CompaniesS&P 500
Consensus Rating Score
2.82
2.78
2.53
Consensus RatingModerate BuyModerate BuyModerate Buy
Predicted Upside2.01% Upside18,254.27% Upside10.64% Upside
News Sentiment Rating
Positive News

See Recent RMD News
Positive News
Positive News
DateBrokerageAnalystActionRatingPrice TargetReport Date
Upside/Downside
Details
9/2/2025CLSA
1 of 5 stars
 UpgradeHoldOutperform
8/1/2025William Blair
2 of 5 stars
 UpgradeStrong-Buy
8/1/2025UBS Group
4 of 5 stars
Laura Sutcliffe
Not Rated
Boost TargetBuy$285.00 ➝ $325.00+16.25%
8/1/2025Royal Bank Of Canada
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost TargetOutperform$294.00 ➝ $300.00+7.31%
8/1/2025Stifel Nicolaus
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost TargetHold$240.00 ➝ $270.00-3.42%
8/1/2025Mizuho
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost TargetOutperform$270.00 ➝ $290.00+3.73%
8/1/2025KeyCorp
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost TargetOverweight$274.00 ➝ $298.00+9.49%
8/1/2025Piper Sandler
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost TargetNeutral$248.00 ➝ $270.00-0.79%
5/20/2025Morgan Stanley
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Set TargetOverweight$286.00+16.50%
4/24/2025JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost TargetOverweight$286.00 ➝ $290.00+22.49%
3/5/2025Citigroup
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeNeutralBuy
1/31/2025Needham & Company LLC
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingHold
1/16/2025The Goldman Sachs Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageBuy
10/25/2024Robert W. Baird
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
 Boost TargetOutperform$280.00 ➝ $283.00+18.39%
9/26/2024Bank of America
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
 Boost TargetBuy$240.00 ➝ $270.00+11.12%
9/24/2024Baird R W
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeStrong-Buy
9/18/2024Wolfe Research
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingPeer PerformUnderperform$180.00-28.25%
6/25/2024Oppenheimer
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
 DowngradeOutperformMarket Perform
10/5/2023Jefferies Financial Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
 Lower Target$240.00 ➝ $165.00+11.49%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Wednesday at 03:04 PM ET.


Should I Buy ResMed Stock? RMD Pros and Cons Explained

These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Friday, September 12, 2025. Please send any questions or comments about these ResMed pros and cons to contact@marketbeat.com.

ResMed
Bull Case

green Wall Street bull icon

Here are some ways that investors could benefit from investing in ResMed Inc.:

  • ResMed Inc. recently reported strong quarterly earnings, exceeding analysts' expectations with earnings per share of $2.55, indicating robust financial health and operational efficiency.
  • The company has shown a significant year-over-year revenue growth of over 10%, reflecting its ability to expand its market presence and increase sales.
  • ResMed Inc. has increased its quarterly dividend to $0.60 per share, which represents a positive change from the previous dividend, signaling confidence in its ongoing profitability and commitment to returning value to shareholders.
  • The current stock price is around $279, which may be considered attractive for investors looking for growth in the medical equipment sector.
  • With a return on equity of over 25%, ResMed Inc. demonstrates effective management and a strong ability to generate profits from shareholders' investments.

ResMed
Bear Case

red Wall Street bear icon

Investors should be bearish about investing in ResMed Inc. for these reasons:

  • Insider selling has been observed, with significant shares sold by both the Director and CEO, which may raise concerns about the company's future prospects and insider confidence.
  • The dividend payout ratio is approximately 25.24%, which, while sustainable, indicates that a significant portion of earnings is retained for reinvestment rather than distributed to shareholders.
  • Corporate insiders own only 0.71% of the company's stock, suggesting limited alignment between management and shareholder interests, which could impact decision-making.
  • Despite recent growth, the medical equipment market can be highly competitive and subject to regulatory changes, which may pose risks to future performance.
  • Market volatility can affect stock prices, and any downturn in the healthcare sector could negatively impact ResMed Inc.'s stock performance.

RMD Forecast - Frequently Asked Questions

According to the research reports of 17 Wall Street equities research analysts, the average twelve-month stock price forecast for ResMed is $278.36, with a high forecast of $325.00 and a low forecast of $180.00.

17 Wall Street analysts have issued "buy," "hold," and "sell" ratings for ResMed in the last year. There is currently 1 sell rating, 3 hold ratings, 11 buy ratings and 2 strong buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" RMD shares.

According to analysts, ResMed's stock has a predicted upside of 2.00% based on their 12-month stock forecasts.

Over the previous 90 days, ResMed's stock had 3 upgrades by analysts.

ResMed has been rated by research analysts at CLSA, KeyCorp, Mizuho, Piper Sandler, Royal Bank Of Canada, Stifel Nicolaus, UBS Group, and William Blair in the past 90 days.

Analysts like ResMed more than other "medical" companies. The consensus rating score for ResMed is 2.82 while the average consensus rating score for "medical" companies is 2.78. Learn more on how RMD compares to other companies.


This page (NYSE:RMD) was last updated on 9/17/2025 by MarketBeat.com Staff
From Our Partners